TKG Therapeutics to Present Proprietary Platform at Biotech Showcase 2026 in San Francisco

TKG Therapeutics is pleased to announce its selection to present at the Biotech Showcase 2026 (Seed Showcase) in San Francisco.

We will introduce our proprietary dual hairpin DNA platform, a novel approach that self-assembles within cancer cells triggered by onco-miRs. This platform simultaneously induces programmed cell death and activates an anti-tumor immune response.

We look forward to connecting with investors, pharma partners, and innovators focused on advancing next-generation oncology therapeutics.

Details about Biotech Showcase 2026 can be found here: https://informaconnect.com/biotech-showcase/